Clinical Trial News and Research

RSS

Oncolytics announces interim data from REOLYSIN translational clinical trial in metastatic colorectal cancer

Oncolytics Biotech Inc. today announced interim data from a U.K. translational clinical trial (REO 013) investigating intravenous administration of REOLYSIN in patients with metastatic colorectal cancer prior to surgical resection of liver metastases. The principal investigator of the study was Professor Alan Melcher of Leeds Institute of Molecular Medicine, University of Leeds, UK.

20 Apr 2011

PCRF awards $1.15 million grant to Children's Hospital Los Angeles

The Pediatric Cancer Research Foundation (PCRF) has awarded a five-year, $1.15 million grant to support the Clinical Trials Program in the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles.

20 Apr 2011

Whole-genome sequencing could soon improve cancer survival rates

Cancer survival rates could improve soon with whole-genome sequencing, according to two studies published in the April 20, 2011, issue of the Journal of the American Medical Association that describe the first clinical applications of the high-tech process in patients with cancer.

20 Apr 2011

Cmed Group selected to help PDPs develop new medicines in Third-World Countries

Cmed Group, an innovative clinical trials services and advanced software provider, announced today that it has been selected as one of six preferred providers offering its clinical research expertise to a consortium of 14 global health Product Development Partnerships (PDPs). The PDPs are working to develop and deliver affordable treatments and vaccines that will help improve the lives of the some of the world's most vulnerable people, especially those in developing countries.

20 Apr 2011

Study shows possibility of women living with AIDS to breastfeed with lower risk

In low-income countries, 1.4 million women are living with the Aids virus. If no prevention measures are taken, the risk for future mothers of transmitting HIV to their child in utero, during delivery or when breastfeeding is 35%.

20 Apr 2011

Swinburne University of Technology acquires Elekta's Neuromag TRIUX MEG system

Certain brain processes happen in the blink of an eye – and even faster – which has made pinpointing these events virtually impossible. The advent of magnetoencephalography (MEG) changed all that, enabling researchers to capture brain electrical activity measured in milliseconds, and offering the potential to reveal the nature of innumerable brain disorders and diseases.

From Elekta 20 Apr 2011

Scientists detect several biomarkers to screen active drugs for Batten disease

Goethe University and Harvard Medical School start screening for active ingredients for the treatment of Batten disease

20 Apr 2011

Biothera's Phase II clinical trials in lung cancer attain stage 1 endpoint

Biothera announced today that its second Phase II non-small cell lung cancer trial, evaluating Imprime PGG® in combination with bevacizumab (Avastin®) and two chemotherapeutic agents, has achieved its stage 1 endpoint and has begun enrolling patients for stage 2 of the study.

20 Apr 2011

SERI selects AB SCIEX TripleTOF 5600 system to test chronic eye inflammations

AB SCIEX, a global leader in life science analytical technologies, today announced that the Singapore Eye Research Institute, an internationally known eye research center, will advance biomarker candidates it identified for chronic inflammatory eye conditions into large-scale clinical trials for validation with the AB SCIEX TripleTOF™ 5600 System.

20 Apr 2011

Tissue Genesis commences PVD clinical trials with adipose-derived adult stem cell-coated vascular grafts

Tissue Genesis, Inc., an emerging leader in adult stem cell and regenerative medicine, announced today that it has begun clinical trials for peripheral vascular disease (PVD) with adipose (fat) derived adult stem cell-coated vascular grafts at the University of Louisville Hospital. Tissue Genesis is the first to initiate a FDA-approved trial using the patient's own adipose-derived adult stem cells (ASCs) prepared at the point-of-care.

20 Apr 2011

Cord blood units treated with signaling molecule show favorable safety profile in long-term animal studies

An innovative experimental treatment for boosting the effectiveness of stem-cell transplants with umbilical cord blood has a favorable safety profile in long-term animal studies, report scientists from Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, and Children's Hospital Boston.

20 Apr 2011

Loyola enrolls patients in clinical trial for open-heart valve replacement surgery

Loyola University Hospital is enrolling patients in a clinical trial that offers an alternative to traditional open-heart surgery for patients who need new aortic heart valves.

20 Apr 2011

Forest Labs fourth quarter net sales increase 9.7% to $1,091.9 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $1.12 in the fourth quarter of fiscal 2011.

19 Apr 2011

Novartis NVA23 Phase III trial in COPD achieves primary end point

Sosei Group Corporation announces that NVA237, a long-acting muscarinic antagonist being investigated as a once daily treatment for chronic obstructive pulmonary disease, achieved its primary end point in a Phase III study.

19 Apr 2011

Seattle enters second ADC research collaboration agreement with Genmab

Genmab A/S and Seattle Genetics, Inc. announced today that the companies have entered into a second antibody-drug conjugate research collaboration agreement.

19 Apr 2011

Abiomed to present new data from PROTECT II study in PCI at SCAI meeting

Abiomed Inc., a leading provider of breakthrough heart support technologies, today announced that new data from the PROTECT II study will be presented by William O'Neill, M.D., executive dean for clinical affairs at the University of Miami Miller School of Medicine, and principal investigator for the PROTECT II study, during the late-breaking clinical trials session at the Society for Cardiovascular Angiography and Interventions 2011 Scientific Sessions in Baltimore, Maryland.

19 Apr 2011

BioSante, Aduro BioTech enter license agreement for GVAX cancer vaccines

Aduro BioTech, a clinical-stage immunotherapy company, has licensed GVAX Pancreas Cancer Vaccine and GVAX Prostate Cancer Vaccine BioSante Pharmaceuticals, Inc. in exchange for milestone and royalty payments after commercialization.

19 Apr 2011

Well-controlled blood sugar levels linked to low risk of diabetic complications

A new study of older diabetes patients has found that well-controlled blood sugar levels were associated with a lower risk of major complications such as heart attacks, amputation and kidney disease, but the very lowest blood sugar levels were associated with a small but significant increased risk of death.

19 Apr 2011

BioSante licenses Pancreas and Prostate cancer vaccines to Aduro BioTech

BioSante Pharmaceuticals, Inc. today announced it has licensed its Pancreas Cancer Vaccine and Prostate Cancer Vaccine to Aduro BioTech, a clinical-stage immunotherapy company, solely for use in combination with Aduro's proprietary vaccine platform based on Listeria monocytogenes (Lm).

19 Apr 2011

Journal of Clinical Oncology publishes CytRx tamibarotene Phase 2b trial results in APL

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the publication of a case report in the peer-reviewed Journal of Clinical Oncology documenting the use of tamibarotene in the successful treatment of a patient with recurrent advanced-stage acute promyelocytic leukemia.

19 Apr 2011